{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:29:55Z","timestamp":1790890195744,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The increase in cancer-specific mortality (CSM) associated with pathologically confirmed adjacent organ invasion (pT4) in non-metastatic (M0) renal cell carcinoma (RCC), relative to limited local invasion (pT3) or no local invasion (pT2) with otherwise same patient and tumor characteristics, is unknown. We addressed this knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within the Surveillance, Epidemiology, and End Results database (2004\u20132022), M0 RCC patients treated with radical nephrectomy were identified. Propensity score matching (PSM) was applied, and multivariable competing-risks regression (CRR) models were fitted. Additional sensitivity analyses were performed to evaluate the robustness of the primary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 27,859 patients, 666 (2.4%) were classified as pT4, 15,343 (55.1%) as pT3, and 11,850 (42.5%) as pT2. After PSM, CSM at 120 months was 63.0% in pT4 versus 43.2% in pT3 and 26.0% in pT2. In multivariable CRR models, pT4 was associated with 1.84-fold higher CSM compared with pT3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and 3.31-fold higher CSM compared with pT2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In sensitivity analyses restricted to patients with clear-cell RCC, patients diagnosed before approval of adjuvant systemic therapy, and patients without lymph node invasion, corresponding effect estimates ranged from 1.79 to 1.93 for the comparison with pT3 and from 2.96 to 3.47 for the comparison with pT2 (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In M0 RCC, the presence of adjacent organ invasion (pT4) doubles the rate of CSM relative to pT3 and triples the rate of CSM relative to pT2 when all other tumor and patient characteristics are held constant. These findings quantify the very aggressive nature of pT4 independent of other tumor and patient characteristics and thereby validate contemporary T staging. Accordingly, more frequent follow-up and prioritization of pT4 patients for discussions regarding adjuvant systemic therapy may be warranted compared with their pT3 and pT2 counterparts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04511-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:55:04Z","timestamp":1784519704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic impact of adjacent organ invasion on cancer-specific mortality in non-metastatic renal cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5715-9965","authenticated-orcid":false,"given":"Maximilian","family":"Filzmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Petix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam I.","family":"Traumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.-H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"2","key":"4511_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4511_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/mco.2023.2607","volume":"18","author":"SM Fateh","year":"2023","unstructured":"Fateh SM, Arkawazi LA, Tahir SH, et al. Renal cell carcinoma T staging: Diagnostic accuracy of preoperative contrast-enhanced computed tomography. Mol Clin Oncol. 2023;18(2):11. https:\/\/doi.org\/10.3892\/mco.2023.2607.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"4511_CR3","first-page":"22","volume":"15","author":"A T\u00fcrkvatan","year":"2009","unstructured":"T\u00fcrkvatan A, Akdur PO, Altinel M, et al. Preoperative staging of renal cell carcinoma with multidetector CT. Diagn Interv Radiol. 2009;15(1):22\u201330.","journal-title":"Diagn Interv Radiol"},{"issue":"2","key":"4511_CR4","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.clgc.2018.07.024","volume":"17","author":"C Vogel","year":"2019","unstructured":"Vogel C, Ziegelm\u00fcller B, Ljungberg B, et al. Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin Genitourin Cancer. 2019;17(2):e345\u201355. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.024.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"4511_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00345-011-0816-7","volume":"31","author":"AS El-Hefnawy","year":"2013","unstructured":"El-Hefnawy AS, Mosbah A, El-Diasty T, Hassan M, Shaaban AA. Accuracy of multi-detector computed tomography (MDCT) in staging of renal cell carcinoma (RCC): analysis of risk factors for mis-staging and its impact on surgical intervention. World J Urol. 2013;31(4):887\u201391. https:\/\/doi.org\/10.1007\/s00345-011-0816-7.","journal-title":"World J Urol"},{"issue":"3","key":"4511_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2214\/ajr.21.25493","volume":"217","author":"AA Elkassem","year":"2021","unstructured":"Elkassem AA, Allen BC, Sharbidre KG, Rais-Bahrami S, Smith AD. Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the AJR Special Series on Cancer Staging. Am J Roentgenol. 2021;217(3):541\u201355. https:\/\/doi.org\/10.2214\/ajr.21.25493.","journal-title":"Am J Roentgenol"},{"issue":"1","key":"4511_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2214\/ajr.182.1.1820217","volume":"182","author":"FB Ergen","year":"2004","unstructured":"Ergen FB, Hussain HK, Caoili EM, et al. MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: comparison with surgical and pathologic staging. AJR Am J Roentgenol. 2004;182(1):217\u201325. https:\/\/doi.org\/10.2214\/ajr.182.1.1820217.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"4511_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5489\/cuaj.5941","volume":"14","author":"JD Oake","year":"2020","unstructured":"Oake JD, Patel P, Lavall\u00e9e LT, et al. Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Can Urol Assoc J. 2020;14(2):24\u201330. https:\/\/doi.org\/10.5489\/cuaj.5941.","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"4511_CR9","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/cncr.22629","volume":"109","author":"V Margulis","year":"2007","unstructured":"Margulis V, S\u00e1nchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer. 2007;109(10):2025\u201330. https:\/\/doi.org\/10.1002\/cncr.22629.","journal-title":"Cancer"},{"issue":"1","key":"4511_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cncr.21125","volume":"104","author":"RH Thompson","year":"2005","unstructured":"Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53\u201360. https:\/\/doi.org\/10.1002\/cncr.21125.","journal-title":"Cancer"},{"issue":"1","key":"4511_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.euf.2021.02.009","volume":"8","author":"L Nocera","year":"2022","unstructured":"Nocera L, Coll\u00e0 Ruvolo C, Stolzenbach LF, et al. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. Eur Urol Focus. 2022;8(1):182\u201390. https:\/\/doi.org\/10.1016\/j.euf.2021.02.009.","journal-title":"Eur Urol Focus"},{"key":"4511_CR12","doi-asserted-by":"publisher","unstructured":"Ficarra V, Galfano A, Guill\u00e9 F et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007;178(2):418\u2009\u2013\u200924;23\u2009\u2013\u20094 https:\/\/doi.org\/10.1016\/j.juro.2007.03.104","DOI":"10.1016\/j.juro.2007.03.104"},{"issue":"4","key":"4511_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2010.07.006","volume":"58","author":"G Novara","year":"2010","unstructured":"Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol. 2010;58(4):588\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2010.07.006.","journal-title":"Eur Urol"},{"issue":"3","key":"4511_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2006.02.034","volume":"50","author":"PI Karakiewicz","year":"2006","unstructured":"Karakiewicz PI, Lewinshtein DJ, Chun FK, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol. 2006;50(3):521\u2013829. https:\/\/doi.org\/10.1016\/j.eururo.2006.02.034.","journal-title":"Eur Urol"},{"issue":"5","key":"4511_CR15","doi-asserted-by":"publisher","first-page":"e23719","DOI":"10.1016\/j.urolonc.2015.11.020","volume":"34","author":"LD Borregales","year":"2016","unstructured":"Borregales LD, Kim DY, Staller AL, et al. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016;34(5):e23719\u201326. https:\/\/doi.org\/10.1016\/j.urolonc.2015.11.020.","journal-title":"Urol Oncol"},{"issue":"8","key":"4511_CR16","doi-asserted-by":"publisher","first-page":"111924","DOI":"10.1016\/j.ejso.2026.111924","volume":"52","author":"M Filzmayer","year":"2026","unstructured":"Filzmayer M, Quarta L, Petix M, et al. Rates of adjacent organ invasion in non-metastatic renal cell carcinoma: a population-based study. Eur J Surg Oncol. 2026;52(8):111924. https:\/\/doi.org\/10.1016\/j.ejso.2026.111924.","journal-title":"Eur J Surg Oncol"},{"key":"4511_CR17","unstructured":"Surveillance. Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2025, based on the November 2024 submission."},{"issue":"446","key":"4511_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94(446):496\u2013509. https:\/\/doi.org\/10.2307\/2670170.","journal-title":"J Am Stat Assoc"},{"issue":"23","key":"4511_CR19","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016;375(23):2246\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1611406.","journal-title":"N Engl J Med"},{"issue":"1","key":"4511_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","volume":"73","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2018;73(1):62\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.008.","journal-title":"Eur Urol"},{"issue":"8","key":"4511_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2106391.","journal-title":"N Engl J Med"},{"issue":"15","key":"4511_CR22","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;390(15):1359\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2312695.","journal-title":"N Engl J Med"},{"key":"4511_CR23","unstructured":"European Association of Urology. EAU Guidelines. Edition presented at the EAU Annual Congress in London. Secondary European Association of Urology: EAU Guidelines. Edition presented at the EAU Annual Congress in London 2026."},{"key":"4511_CR24","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Kidney Cancer. Version 3. Secondary NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer. Version 3 2025."},{"issue":"1","key":"4511_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12957-017-1257-6","volume":"15","author":"Y Abu-Ghanem","year":"2017","unstructured":"Abu-Ghanem Y, Ramon J, Berger R, et al. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival. World J Surg Oncol. 2017;15(1):193. https:\/\/doi.org\/10.1186\/s12957-017-1257-6.","journal-title":"World J Surg Oncol"},{"key":"4511_CR26","doi-asserted-by":"publisher","unstructured":"Garofano G, Saitta C, Musso G, et al. Positive Surgical Margins in Clear Cell Renal Cell Carcinoma: Prognostic Impact and Implications for Risk Stratification and Adjuvant Therapy. J Clin Med. 2025;14(11). https:\/\/doi.org\/10.3390\/jcm14113908.","DOI":"10.3390\/jcm14113908"},{"key":"4511_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-026-05141-0","author":"M Filzmayer","year":"2026","unstructured":"Filzmayer M, Polverino F, Petix M, et al. Racial\/ethnic differences in time to nephrectomy and its association with cancer-specific mortality in localized renal cell carcinoma. Int Urol Nephrol. 2026. https:\/\/doi.org\/10.1007\/s11255-026-05141-0.","journal-title":"Int Urol Nephrol"},{"key":"4511_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-026-03038-3","author":"M Filzmayer","year":"2026","unstructured":"Filzmayer M, Polverino F, Petix M, et al. Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans. J Racial Ethn Health Disparities. 2026. https:\/\/doi.org\/10.1007\/s40615-026-03038-3.","journal-title":"J Racial Ethn Health Disparities"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04511-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:02:06Z","timestamp":1784566926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4511"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04511-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study and requirement for informed consent was waived by the Institutional Review Board (Comit\u00e9 d\u2019\u00e9thique \u00e0 la recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al) due to the retrospective nature of the study and the use of anonymized data from the SEER database.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not contain any individual person\u2019s identifiable information.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"304"}}